Serum Pepsinogen as a Biomarker for Gastric Cancer in the United States: A Nested Case-Control Study Using the PLCO Cancer Screening Trial Data
- PMID: 35534235
- PMCID: PMC9268394
- DOI: 10.1158/1055-9965.EPI-21-1328
Serum Pepsinogen as a Biomarker for Gastric Cancer in the United States: A Nested Case-Control Study Using the PLCO Cancer Screening Trial Data
Abstract
Background: Gastric cancer lacks specific symptoms, resulting in diagnosis at later stages and high mortality. Serum pepsinogen is a biomarker for atrophic gastritis, a gastric cancer precursor, and may be useful to detect persons at increased risk of gastric cancer.
Methods: The Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial was conducted in the United States between 1993 and 2001. ELISA-based pepsinogen tests were conducted on prediagnostic serum samples of 105 PLCO participants who developed gastric cancer and 209 age, sex, and race-matched controls. Pepsinogen positive (PG+) was defined as pepsinogen I ≤ 70 μg/L and pepsinogen I/II ratio ≤3.0. Results of conditional logistic regression models, and sensitivity and specificity, of PG+ for gastric cancer are reported.
Results: Gastric cancer cases were more likely to be PG+ (31.4% vs. 5.5%, P < 0.001) at baseline than controls. Compared to PG-, PG+ was associated with an 8.5-fold increased risk for gastric cancer [95% confidence interval (CI) = 3.8-19.4]. This risk remained significant after adjusting for Helicobacter pylori, family history of gastric cancer, education, smoking, and BMI (aOR, 10.6; 95% CI, 4.3-26.2). In subgroup analysis, PG+ individuals were 11-fold more like to develop non-cardia gastric cancer (OR, 11.1; 95% CI, 4.3-28.8); conversely, they were not significantly more likely to develop cardia gastric cancer (OR, 2.0; 95% CI = 0.3-14.2). PG+ status yielded low sensitivity but high specificity for both noncardia (44.3%; 93.6%) and cardia gastric cancer (5.7%; 97.2%).
Conclusions: Prediagnostic serum pepsinogen levels from a large, prospective cohort study were associated with risk of gastric cancer, particularly noncardia gastric cancer.
Impact: PG status may identify individuals at higher risk of noncardia gastric cancer for targeted screening or interventions. See related commentary by Zhou and Huang, p. 1257.
©2022 American Association for Cancer Research.
Comment in
-
Catching Up with the World: Pepsinogen Screening for Gastric Cancer in the United States.Cancer Epidemiol Biomarkers Prev. 2022 Jul 1;31(7):1257-1258. doi: 10.1158/1055-9965.EPI-22-0372. Cancer Epidemiol Biomarkers Prev. 2022. PMID: 35775231
Similar articles
-
Catching Up with the World: Pepsinogen Screening for Gastric Cancer in the United States.Cancer Epidemiol Biomarkers Prev. 2022 Jul 1;31(7):1257-1258. doi: 10.1158/1055-9965.EPI-22-0372. Cancer Epidemiol Biomarkers Prev. 2022. PMID: 35775231
-
Effect of Helicobacter pylori infection combined with CagA and pepsinogen status on gastric cancer development among Japanese men and women: a nested case-control study.Cancer Epidemiol Biomarkers Prev. 2006 Jul;15(7):1341-7. doi: 10.1158/1055-9965.EPI-05-0901. Cancer Epidemiol Biomarkers Prev. 2006. PMID: 16835334
-
[Diagnostic Value of Serum Pepsinogen Ⅰ/Pepsinogen Ⅱ Combined with Tumor Markers for Helicobacter pylori-Positive Early-Stage Gastric Cancer].Sichuan Da Xue Xue Bao Yi Xue Ban. 2023 Jan;54(1):186-191. doi: 10.12182/20230160111. Sichuan Da Xue Xue Bao Yi Xue Ban. 2023. PMID: 36647665 Free PMC article. Chinese.
-
Pepsinogen II in gastritis and Helicobacter pylori infection.Helicobacter. 2022 Apr;27(2):e12872. doi: 10.1111/hel.12872. Epub 2022 Jan 8. Helicobacter. 2022. PMID: 34997989 Review.
-
Using serum pepsinogens wisely in a clinical practice.J Dig Dis. 2007 Feb;8(1):8-14. doi: 10.1111/j.1443-9573.2007.00278.x. J Dig Dis. 2007. PMID: 17261129 Review.
Cited by
-
Controlling Gastric Cancer in a World of Heterogeneous Risk.Gastroenterology. 2023 Apr;164(5):736-751. doi: 10.1053/j.gastro.2023.01.018. Epub 2023 Jan 24. Gastroenterology. 2023. PMID: 36706842 Free PMC article. Review.
-
Serum levels of oxidative stress, IL-8, and pepsinogen I/II ratio in Helicobacter pylori and gastric cancer patients: potential diagnostic biomarkers.BMC Gastroenterol. 2025 Jan 2;25(1):2. doi: 10.1186/s12876-024-03564-6. BMC Gastroenterol. 2025. PMID: 39748276 Free PMC article.
-
Chronic atrophic gastritis and risk of incident upper gastrointestinal cancers: a systematic review and meta-analysis.J Transl Med. 2024 May 6;22(1):429. doi: 10.1186/s12967-023-04736-w. J Transl Med. 2024. PMID: 38711123 Free PMC article.
-
Analysis of high risk factors for chronic atrophic gastritis.Saudi J Gastroenterol. 2023 Mar-Apr;29(2):127-134. doi: 10.4103/sjg.sjg_383_22. Saudi J Gastroenterol. 2023. PMID: 36588366 Free PMC article.
-
The Therapeutic Potential of Bombyx Batryticatus for Chronic Atrophic Gastritis Precancerous Lesions via the PI3K/AKT/mTOR Pathway Based on Network Pharmacology of Blood-Entering Components.Pharmaceuticals (Basel). 2025 May 25;18(6):791. doi: 10.3390/ph18060791. Pharmaceuticals (Basel). 2025. PMID: 40573188 Free PMC article.
References
-
- Onodera H, Tokunaga A, Yoshiyuki T, Kiyama T, Kato S, Matsukura N, et al. Surgical outcome of 483 patients with early gastric cancer: prognosis, postoperative morbidity and mortality, and gastric remnant cancer. Hepato-gastroenterology 2004;51(55):82–5. - PubMed
-
- Correa P. Human gastric carcinogenesis: a multistep and multifactorial process--First American Cancer Society Award Lecture on Cancer Epidemiology and Prevention. Cancer Res 1992;52(24):6735–40. - PubMed
-
- Correa P, Shiao YH. Phenotypic and genotypic events in gastric carcinogenesis. Cancer Res 1994;54(7 Suppl):1941s-3s. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical